View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 14, 2011

Sanofi-Aventis and Regeneron Present Sarilumab Study Results

Sanofi-Aventis and Regeneron Pharmaceuticals have reported clinical results from two Phase IIb studies of Sarilumab in rheumatoid arthritis and ankylosing spondylitis patients. Sarilumab is a novel, high-affinity, subcutaneously administered, fully-human antibody that targets the interl

By cms admin

Sanofi-Aventis and Regeneron Pharmaceuticals have reported clinical results from two Phase IIb studies of Sarilumab in rheumatoid arthritis and ankylosing spondylitis patients.

Sarilumab is a novel, high-affinity, subcutaneously administered, fully-human antibody that targets the interleukin-6 receptor.

The 306 patient, dose-ranging, multi-national, randomised, multi-arm, double-blind and placebo-controlled MOBILITY trial demonstrated that patients treated with Sarilumab in combination with methotrexate achieved improvement in signs and symptoms of rheumatoid arthritis at 12 weeks.

Sanofi-Aventis global research and development president Elias Zerhouni said that the companies are discussing the dosage of Sarilumab to advance into the Phase III portion of the MOBILITY trial.

Another randomised, double-blind, placebo-controlled, dose ranging study including 300 patients, known as ALIGN, showed the drug did not demonstrate significant and clinically meaningful improvements in signs and symptoms of active ankylosing spondylitis compared to a placebo.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology